Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 2
2009 3
2010 1
2011 2
2012 3
2013 3
2014 3
2015 4
2016 8
2017 3
2018 4
2019 7
2020 6
2021 4
2022 3
2024 6
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Galiè N, et al. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. N Engl J Med. 2015. PMID: 26308684 Free article. Clinical Trial.
METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization functional class II or III symptoms of pulmonary arterial hypertension who had not previously received treatment to receive initial combination t …
METHODS: In this event-driven, double-blind study, we randomly assigned, in a 2:1:1 ratio, participants with World Health Organization funct …
Bosentan and ambrisentan in the treatment of idiopathic pulmonary fibrosis: a meta-analysis.
Li HF, Wang JX, Xie ZF, Li LH, Li B, Huang FF, Li J, Zhou XL. Li HF, et al. Eur Rev Med Pharmacol Sci. 2024 Feb;28(3):1183-1193. doi: 10.26355/eurrev_202402_35357. Eur Rev Med Pharmacol Sci. 2024. PMID: 38375723 Free article.
OBJECTIVE: The aim is to showcase the effectiveness and safety of bosentan or ambrisentan in individuals diagnosed with idiopathic pulmonary fibrosis (IPF) and offer fresh evidence for the management of this condition. ...The findings of this research do not endorse the ut …
OBJECTIVE: The aim is to showcase the effectiveness and safety of bosentan or ambrisentan in individuals diagnosed with idiopathic pu …
Ambrisentan May Improve Exercise Tolerance and Cardiac Function in Patients With Pulmonary Hypertension.
Li XQ, Li YJ, Wang Y. Li XQ, et al. Clin Ther. 2015 Jun 1;37(6):1270-9. doi: 10.1016/j.clinthera.2015.03.011. Epub 2015 Apr 7. Clin Ther. 2015. PMID: 25862136 Review.
PURPOSE: Pulmonary hypertension (PH) is characterized by a significant increase in pulmonary vascular resistance, which results in ventricular failure and death. Ambrisentan appears to be an effective treatment in the pathogenesis and progression of ambrisentan, but …
PURPOSE: Pulmonary hypertension (PH) is characterized by a significant increase in pulmonary vascular resistance, which results in ventricul …
Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial.
Preston IR, Burger CD, Bartolome S, Safdar Z, Krowka M, Sood N, Ford HJ, Battarjee WF, Chakinala MM, Gomberg-Maitland M, Hill NS. Preston IR, et al. J Heart Lung Transplant. 2020 May;39(5):464-472. doi: 10.1016/j.healun.2019.12.008. Epub 2020 Jan 21. J Heart Lung Transplant. 2020. PMID: 32008947 Clinical Trial.
BACKGROUND: Ambrisentan has shown effectiveness in the treatment of Group 1 pulmonary arterial hypertension (PAH). ...One episode of leg edema resulted into the permanent discontinuation of ambrisentan. CONCLUSIONS: Ambrisentan monotherapy in PoPH improves he …
BACKGROUND: Ambrisentan has shown effectiveness in the treatment of Group 1 pulmonary arterial hypertension (PAH). ...One episode of …
Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
Zhao Q, Guo N, Chen J, Parks D, Tian Z. Zhao Q, et al. J Clin Pharm Ther. 2022 Feb;47(2):146-156. doi: 10.1111/jcpt.13481. Epub 2021 Jul 28. J Clin Pharm Ther. 2022. PMID: 34319626 Review.
RESULTS: Five clinical trials from four published studies (total patients: n = 920) were included. Ambrisentan and bosentan showed no significant difference in 6MWD (MD: -1.32; 95% CI: -27.87, 25.31, SUCRA score: ambrisentan 0.73, bosentan 0.77), BDI (MD: -0.16; 95% …
RESULTS: Five clinical trials from four published studies (total patients: n = 920) were included. Ambrisentan and bosentan showed no …
Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA study.
Xanthouli P, Uesbeck P, Lorenz HM, Blank N, Eichstaedt CA, Harutyunova S, Egenlauf B, Coghlan JG, Denton CP, Grünig E, Benjamin N. Xanthouli P, et al. Arthritis Res Ther. 2024 Jul 18;26(1):136. doi: 10.1186/s13075-024-03363-0. Arthritis Res Ther. 2024. PMID: 39026360 Free PMC article. Clinical Trial.
The primary endpoint was to assess whether continued treatment with ambrisentan vs. no treatment prevented the development of PAH according to the new definition. ...There was a significant improvement of mPAP in catheterised patients receiving ambrisentan vs. no PA …
The primary endpoint was to assess whether continued treatment with ambrisentan vs. no treatment prevented the development of PAH acc …
Ambrisentan therapy for pulmonary arterial hypertension.
Galié N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, Zwicke D, Naeije R, Shapiro S, Olschewski H, Rubin LJ. Galié N, et al. J Am Coll Cardiol. 2005 Aug 2;46(3):529-35. doi: 10.1016/j.jacc.2005.04.050. J Am Coll Cardiol. 2005. PMID: 16053970 Free article. Clinical Trial.
OBJECTIVES: The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A receptor-selective antagonist, in patients with pulmonary arterial hypertension (PAH). ...RESULTS: At 12 weeks, ambrisentan increased …
OBJECTIVES: The purpose of this study was to examine the efficacy and safety of four doses of ambrisentan, an oral endothelin type A …
Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu SN, Kilickiran Avci B, Hatemi G. Erdogan M, et al. Intern Emerg Med. 2024 Apr;19(3):731-743. doi: 10.1007/s11739-024-03539-1. Epub 2024 Feb 20. Intern Emerg Med. 2024. PMID: 38378970 Free PMC article.
The pharmacological interventions were epoprostenol, treprostinil, sildenafil, tadalafil, bosentan, macitentan, ambrisentan, riociguat, and selexipag. There was a significant difference between interventions and placebo in FC, 6MWD, CW, PVR, RAP, and CI that favored interv …
The pharmacological interventions were epoprostenol, treprostinil, sildenafil, tadalafil, bosentan, macitentan, ambrisentan, riocigua …
Bioequivalence and Tolerability of Ambrisentan: A Pharmacokinetic Study in Mexican Healthy Male Subjects.
Cárdenas KPC, Velázquez JER, Escobar JJO, Chirinos J, Pendela M. Cárdenas KPC, et al. Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):611-618. doi: 10.1007/s13318-020-00627-3. Eur J Drug Metab Pharmacokinet. 2020. PMID: 32472357 Clinical Trial.
OBJECTIVES: The purpose of this study was to test the bioequivalence, pharmacokinetics, and tolerability of ambrisentan 10 mg tablets. METHODS: In this open-label, randomized, oral single-dose, two-way crossover bioequivalence study, 26 Mexican adult healthy male subjects …
OBJECTIVES: The purpose of this study was to test the bioequivalence, pharmacokinetics, and tolerability of ambrisentan 10 mg tablets …
Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension.
Hatano M, Abe K, Koike G, Takahashi T, Tunmer G, Kiely DG. Hatano M, et al. Int Heart J. 2022;63(1):99-105. doi: 10.1536/ihj.21-497. Int Heart J. 2022. PMID: 35095084 Free article. Clinical Trial.
The AMBITION study (NCT01178073) provided the first long-term clinical evidence for initial combination therapy with ambrisentan and tadalafil in patients with pulmonary arterial hypertension (PAH). Nevertheless, predictors of treatment response were not assessed.To identi …
The AMBITION study (NCT01178073) provided the first long-term clinical evidence for initial combination therapy with ambrisentan and …
54 results